author:admin    comment:0   view:132   userful 1

Transave Inc. today reported positive results from a Phase II clinical trial in non-cystic fibrosis bronchiectasis patients for its lead investigational drug ARIKACE . The Phase II data indicated that ARIKACE delivered once daily for 28 consecutive days demonstrated superior clinical benefit co ...